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Abstract
Introduction: Severe sepsis is associated with an unacceptably high rate of mortality. Recent studies revealed
elevated levels of vascular endothelial growth factor (VEGF), a potent angiogenic and vascular permeability factor,
in patients with sepsis. There was also an association between VEGF levels and sepsis severity. Here we investigate
the effects of an anti-VEGF antibody (Bevacizumab, Bev) in an experimental model of sepsis.
Methods: Human umbilical vein endothelial cells (HUVECs), murine cecal ligation and puncture (CLP), and
endotoxemia models of sepsis were used. HUVECs were treated with lipopolysaccharide (LPS) and/or Bev,
harvested and cytokine mRNA levels determined using a semi-quantitative reverse transcription-polymerase chain
reaction assay. The levels of inflammatory cytokine were also determined in HUVECs supernatants. In addition, the
effects of Bev on mortality in the CLP and endotoxemia models of sepsis were evaluated.
Results: Treatment with Bev and LPS significantly decreased the expression and the level of inflammatory
cytokines in HUVECs relative to LPS alone. In CLP and endotoxemia models, survival benefits were evident in mice
given 0.1 mg/kg of Bev relative to the CLP or LPS alone (P <0.001 and P = 0.028, respectively), and in 6 h post-
treated mice relative to the CLP alone for the effect of different time of Bev (P = 0.033). In addition, Bev treatment
inhibited LPS-induced vascular leak in the lung, spleen and kidney in the murine endotoxemia model (P <0.05).
Conclusions: Anti-VEGF antibody may be a promising therapeutic agent due to its beneficial effects on the
survival of sepsis by decreasing inflammatory responses and endothelial permeability.
Keywords: sepsis, vascular endothelial growth factor, bevacizumab, anti-VEGF antibody
Introduction
Sepsis, the systemic inflammatory response to infection,
is a leading cause of morbidity and mortality. Although
the pathways that are activated during sepsis have been
characterized extensively, much remains to be learned
about the mechanisms underlying sepsis-induced organ
failure. Thus far, efforts to block individual components
of the inflammatory or coagulation pathways have had
little impact on survival. Tumor necrosis factor-a (TNF-
a) is one of the most potent pro-inflammatory cytokines
identified in sepsis. However, a disconnect exists between
hyper-acute experimental animal models and human sep-
sis illustrated by the failure of several clinical trials of
anti-TNF-a monoclonal antibodies [1,2]. In addition, a
recent randomized controlled trial using recombinant
activated protein C (rhAPC) found no benefit, prompting
withdrawal of this drug from the market [3]. Thus, mor-
tality rates remain close to 25 to 30%. Clearly, future
advances in therapy will be contingent upon an improved
understanding of sepsis pathophysiology.
Vascular endothelial growth factor (VEGF) was first
identified and characterized as a vascular permeability
factor and then subsequently reported to promote prolif-
eration, migration and survival of endothelial cells [4-6].
VEGF (also termed VEGF-A) is a member of a growing
family of related proteins that include VEGF-B, -C, -D
and placental growth factor (PIGF) [7]. VEGF binds to
two transmembrane receptors, namely Flt-1 and Flk-1,
whereas PIGF binds to Flt-1 alone. Within the vessel
* Correspondence: jmkim@yuhs.ac
Department of Internal Medicine and AIDS Research Institute, Yonsei
University College of Medicine, Seoul, Republic of Korea
Jeong et al. Critical Care 2013, 17:R97
http://ccforum.com/content/17/3/R97
© 2013 Jeong et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
wall, Flk-1 is selectively expressed in the endothelium.
Flt-1 is present on both endothelial cells and monocytes.
In addition to its role in promoting endothelial perme-
ability and proliferation, VEGF may contribute to inflam-
mation and coagulation. For example, VEGF induces the
expression of cellular adhesion molecules including
E-selectin, intercellular adhesion molecule 1 (ICAM-1),
and vascular cell adhesion molecule 1 (VCAM-1) in
endothelial cells and promotes the adhesion of leukocytes
[8,9]. Moreover, VEGF signaling up-regulates tissue fac-
tor mRNA, protein and procoagulant activity [10].
Recently, two independent studies reported an associa-
tion between human sepsis/septic shock and elevated cir-
culating levels of VEGF [11,12].
Bevacizumab (Bev) (Avastin; GeneTech, Inc., San
Francisco, CA, USA) was the first humanized anti-VEGF
neutralizing antibody approved by the Food and Drug
Administration (FDA) for treatment of metastatic colon
cancer [13]. Bev combined with chemotherapy has been
used in clinical trials for several types of cancer [14].
Following the first intravitreal application of Bev in 2005
[15], its off-label use for exudative age-related macular
degeneration is now widespread. However, no studies
have evaluated the effectiveness of Bev in sepsis models.
Therefore, we designed this study to test the hypothesis
that VEGF plays a pathogenic role in mediating sepsis
and that a humanized anti-VEGF neutralizing antibody,
Bev, could be an effective therapeutic agent in a murine
sepsis model. We determined whether Bev can attenuate
lipopolysaccharide (LPS)-induced inflammation and
improve survival. We also assessed whether Bev could
affect expression and/or secretion of pro-inflammatory
cytokines involved in LPS-toll like receptor (TLR)-4
signaling.
Materials and methods
Animal preparation and treatment
C57BL/6 mice were fed a standard laboratory diet with
water ad libitum and treated according to the guidelines
and regulations for the use and care of animals of Yonsei
University, Seoul, Republic of Korea. Mice were seven to
eight weeks of age and weighed 25 to 30 g at the start of
the experiments. Animal experiments were reviewed and
approved by the Institutional Animal Care and Use Com-
mittee of Yonsei University College of Medicine.
Cecal ligation and puncture (CLP) procedures
CLP surgery was performed as described previously [16].
Briefly, the mice were anesthetized with an intraperitoneal
(i.p.) injection of a 200-μL mixture of ketamine (9 mg/mL)
and xylazine (1 mg/mL). The cecum was exteriorized
through a 1 cm midline abdominal incision and then
ligated distal to the ileocecal junction using 5.0 monofila-
ment. Greater than 75% of the cecum was ligated. The
antimesenteric side of the cecum was punctured bilaterally
with a 23-gauge needle. A small amount of luminal
contents was expressed through both puncture sites to
ensure patency. The cecum was returned to the abdominal
cavity, and the fascia and skin incisions were closed with
6.0 monofilament and surgical staples, respectively.
Sham-operated mice underwent identical procedures, but
without ligation and puncture of the cecum. Topical 1%
lidocaine and bacitracin were applied to the surgical site
post-operatively. All animals received a single intramuscu-
lar injection of trovafloxacin (Pfizer, New York, NY, USA)
at a dose of 20 mg/kg and subcutaneous fluid resuscitation
with 1.0 mL normal saline immediately post-surgery.
Experimental design of murine CLP and endotoxemia
models
The study was performed in two murine models of sepsis.
First, we looked at the effect of different doses of Bev on
mortality in the CLP-induced sepsis and endotoxemia
mouse models. In the CLP model, these four groups con-
sisted of the CLP-only group (n = 13) in which only CLP
was performed, the CLP with 0.1 mg/kg Bev group (n =
8), the CLP with 1.0 mg/kg Bev group (n = 8) and a sham-
surgery-only group (negative control, n = 5). The CLP-
only group received only normal saline 1 h before CLP
surgery; and Bev was administered 1 h before CLP surgery.
The sham surgery group also received normal saline at 1 h
before sham surgery. CLP has the disadvantages of vari-
able severity due to differences in experimental proce-
dures. Therefore, compared to the other groups, a larger
number of mice were assigned to the CLP-only group. For
the endotoxemia model, mice received i.p. injections of
LPS (22 mg/kg weight) from E. coli serotype 0111:B4
(Sigma-Aldrich, St. Louis, MO, USA). The four mouse
groups consisted of the LPS-only group (n = 5), the
LPS with 0.1 mg/kg Bev group (n = 10), the LPS with
1.0 mg/kg Bev group (n = 10), and normal-saline-only
group (negative control, n = 5). Bev was injected 1 h
before LPS injection. The survival rate of the mice was
monitored for seven days after surgery in the CLP mouse
model or following LPS injection in the endotoxemia
model.
To determine the impact of the time of Bev administra-
tion on survival in the murine CLP and endotoxemia
models, the mice assigned to each sepsis model were
divided into four groups. For the CLP model, the four
groups consisted of a CLP control group (n = 8) and three
groups treated with 0.1 mg/kg Bev i.p. 1 h before CLP sur-
gery, 6 h after CLP surgery or 12 h after CLP surgery; n =
8, respectively, denoted as the pre-treated CLP, post-trea-
ted CLP 1 or post-treated CLP 2 group. In the endotoxe-
mia model, the four groups consisted of an LPS control
group (n = 8) and three groups treated with 0.1 mg/kg Bev
i.p. 1 h before LPS injection, 6 h after LPS injection or
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12 h after LPS injection; n = 8, respectively, denoted as the
pre-treated LPS, post-treated LPS 1 or post-treated LPS 2
group. The mice were assessed for survival up to seven
days following intervention. Mortality rates were com-
pared among groups.
Permeability assay
The mice were divided into three groups (n = 8, respec-
tively). The control group was treated with normal saline,
the LPS group was treated with 22 mg/kg LPS-only and
the LPS + Bev group was treated with 22 mg/kg LPS and
0.1 mg/kg Bev. Normal saline or Bev was injected 1 h
before LPS administration. Twenty-four hours later, mice
were anesthetized by i.p. injection of 0.5 ml avertin. Next,
100 μl of 1% Evans blue dye in phosphate-buffered saline
(PBS) was injected into the tail vein. Via heart puncture
40 minutes later, mice were perfused with PBS + 2 mM
EDTA for 20 minutes. The liver, lung, kidney and spleen
were harvested and incubated in formamide for three days
to elute the Evans blue dye. The optical density (OD) at
620 nm of the formamide solution was measured [17].
Cell culture and assay of cellular viability
Human umbilical vein endothelial cells (HUVECs) were
purchased from the ATCC (Manassas, VA, USA). Cells
were grown according to the ATCC recommendation in
F-12K Medium (ATCC), consisting of endothelial cell
growth supplement (ECGS, Sigma-Aldrich), heparin
(Sigma-Aldrich) and 10% fetal bovine serum (FBS)
(Gibco, Gaithersburg, MD, USA). Cells were cultured at
37°C in 5% CO2. Cells between passages four and eight
were used for all experiments. A cell counting kit-8
(CCK-8) (Dojindo, Rockville, MD, USA) assay was used
to assess cell viability.
Semi-quantitative RT-PCR for measurement of VEGF and
cytokine expression levels
HUVECs were harvested from culture dishes and seeded in
60 mm dishes at a density of 1,500 cells/well. The cells
were treated with or without Bev 1 h before LPS treatment.
Then, the cells were harvested at 1.5 h, 3 h and 5 h after
LPS treatment (n = 4, per each time). We checked the
expression of mRNA of cytokines at each time point in
duplo and, thereby, determined the point of greatest
mRNA expression. Thus, cells were harvested 3 h after LPS
treatment and VEGF, IL-6, monocyte chemotactic protein-
1(MCP-1), and regulated on activation, normal T-cell
expressed and secreted (RANTES) mRNA levels were
determined using a semi-quantitative reverse transcription-
polymerase chain reaction (RT-PCR) assay. Briefly, total
RNA from HUVECs was isolated using the Easy-spin total
RNA extraction kit (iNtRON, Sungnam, Korea) following
the manufacturer’s instructions. One microgram of total
RNA was reverse transcribed using AccuPower Cycle Script
RT PreMix (Bioneer, Seoul, Korea), and the cDNA product
was amplified with the i-Taq polymerase (iNtRON, Sung-
nam, Korea) using VEGF-specific primers (forward, 5’-
GGTGAGAGGTCTAGTTCCCGA-3’; reverse, 5’-CCATG
AACTTTCTGCTCTCTTG-3’), IL-6-specific primers (for-
ward, 5’-CCACAAGCGCCTTCGGTCCA-3’; reverse, 5’-
GGGCTGAGATGCCGTCGAGGA-3’), MCP-1-specific
primers (forward, 5’-TTCTGTGCCTGCTGCTCATA-3’;
reverse, 5’ CAGATCTCCTTGGCCACAAT-3’), RANTES-
specific primers (forward, 5’-ACAGGTACCATGAAGGT
CTC-3’; reverse, 5’-TCCTAGCTCATCTCCAAAGA-3’), or
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)-
specific primers (forward, 5’-GTCAGTGGTGGACCTG
ACCT-3’; reverse, 5’-TGAGCTTGACAAAGTGGTCG-3’).
The results were quantified using the Multi-gauge ver 3.0
software (Fujifilm, Tokyo, Japan).
Cytokine measurement in HUVECs using ELISA
HUVECs were cultured to 60 to 70% confluency. Media
were removed at 24 h and stored at -70°C until analysis.
Levels of IL-6, MCP-1 and RANTES in HUVEC culture
supernatants were determined using Quantikine enzyme-
linked immunosorbent assay (ELISA) kits. Mouse IL-6 and
MCP-1 ELISA kits were purchased from BD® BD Bios-
ciences (San Diego, CA, USA), mouse RANTES ELISA
kits were purchased from R&D Systems (Minneapolis,
MN, USA). All ELISA kits were used according to the
manufacturer’s recommendations.
Statistical analyses
The non-parametric Mann-Whitney test was used to com-
pare groups. Multiple differences among groups were eval-
uated using one-way ANOVA multiple comparison test.
Survival analyses were performed using Kaplan-Meier
curves and the log-rank test. The numeric data presented
are the means ± standard deviation. Statistical significance
was set at P <0.05. SPSS for Windows, version 18.0 (SPSS
Inc., Chicago, IL, USA) were used for these analyses. In
addition, statistical power was calculated using PASS 2008
(Power Analysis and Sample Size; NCSS, Kaysville, UT,
USA) software.
Results
VEGF mRNA expression in HUVECs
The time course of LPS-induced expression of VEGF
mRNA was assessed initially. VEGF mRNA levels peaked
after 1 to 2 h of LPS stimulation (Figure 1A, B). Thus,
LPS is a potent mediator of VEGF gene expression in
HUVECs.
Bev inhibits the expression and decreases the
concentration of LPS-induced cytokines in HUVECs
Next, the levels of IL-6, MCP-1 and RANTES mRNAs
in HUVECs were determined (Figure 2). Cytokine levels
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in cells treated with LPS and Bev were significantly
changed when compared to cells treated with LPS alone.
For IL-6 and MCP-1, P <0.01 was set at 50 μg/ml Bev;
for RANTES, P <0.01 at both 25 and 50 μg/ml Bev,
respectively. Cytokine levels of in cell culture superna-
tant were also assessed by ELISA (Table 1). IL-6 levels
were significantly lower in LPS + Bev (both 25 and
50 μg/ml) treated groups than in the LPS-only group
(P < 0.01). In addition, MCP-1 and RANTES levels were
significantly decreased when LPS was administered with
50 μg/ml Bev compared to the LPS-only group.
Effect of Bev dose on mortality
All mice in the control groups (sham surgery and non-LPS
treated groups) remained healthy and survived up to seven
days, whereas all mice in the CLP only group died within
three days of surgery. In contrast, at the seventh experi-
mental day in the CLP with 0.1 and 1.0 mg/kg Bev, groups
three and two mice, respectively, were alive. Figure 3A
shows the survival curve for each of the four groups. In
the LPS-induced endotoxemia model, a similar situation
was observed: in the LPS and 0.1 mg/kg Bev group, the
mortality rate was significantly reduced, but not in the
LPS and 1.0 mg/kg Bev group (P = 0.028) (Figure 3B).
Effect of timing of Bev treatment on mortality in the CLP
and endotoxemia models
The effects of delayed administration of 0.1 mg/kg Bev are
shown in Figure 3. The administration of Bev provided
significant protection up to 6 h after CLP (P = 0.033,
Figure 4A). In the endotoxemia model, delaying Bev
administration until 6 h after LPS treatment also showed a
favorable survival trend, but the differences were no longer
significant compared with the LPS-only group (P = 0.082,
Figure 4B).
Effect of Bev on vascular permeability
LPS administration resulted in organ-specific loss of
barrier function, with increased extravasation of Evans
Figure 1 The expression of VEGF mRNA in HUVECs. Human umbilical vein endothelial cells (HUVECs) were stimulated with 1 μg/ml
lipopolysaccharide (LPS) for up to 5 h. Vascular endothelial growth factor (VEGF) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
mRNA levels were semi-quantified by RT-PCR. Error bars represent SD. *P <0.01 compared to non-treated HUVECs (n = 4).
Figure 2 Expression of IL-6, MCP-1 and RANTES in HUVECs after
treatment with LPS and/or bevacizumab. A, cDNA of cytokines and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). B, semi-
quantitative IL-6 levels. C, semi-quantitative monocyte chemotactic
protein-1 (MCP-1) levels. D, semi-quantitative RANTES (regulated on
activation, normal T-cell expressed and secreted) levels. Error bars
represent SD. *P <0.01 when compared to lipopolysaccharide (LPS)-
only treated human umbilical vein endothelial cells (HUVECs) (n = 4).
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blue dye in the liver, lung, spleen and kidneys (Figure 5).
Bev-treatment significantly inhibited vascular permeability
in the lung, spleen and renal parenchyma in the mouse
model of endotoxemia.
Discussion
VEGF, an endothelial growth factor widely known for its
role in the regulation of embryonic and post-natal angio-
genesis, was first characterized as a potent stimulator of
endothelial permeability due to its endothelial barrier-
breaking properties [4]. The clinical relevance of this effect
in humans was reported more than a decade ago, when
patients were treated with low doses of VEGF to boost
revascularization in critical limb ischemia. Peripheral
edema was a recurrent adverse event [18]. Indeed, elevated
VEGF levels are associated with conditions that disrupt
the endothelial barrier, including sepsis [19,20]. Moreover,
levels of VEGF in intensive care patients with sepsis are
associated with disease severity and mortality [11,12]. In
these studies, we demonstrate that an anti-VEGF antibody
protects mice from the lethality of severe peritonitis and
endotoxemia. Thus, inhibition of VEGF activity may con-
tribute to sepsis treatment in the future.
Severe sepsis is a major clinical problem in acute care
medicine and surgery, yet treatment options remain limited
[21,22]. Since severe sepsis is associated with an unaccepta-
bly high mortality rate, an important goal is to identify
novel therapeutic targets. However, further advances in
therapy will be critically dependent on an improved under-
standing of sepsis pathophysiology. In response to a patho-
gen, large quantities of proinflammatory cytokines are
released in an unregulated immune cascade that can cause
multiple organ failure [23,24]. Alterations in the microcir-
culation may play a critical role in the pathophysiology of
sepsis [25]. LPS is one of the most potent microbial media-
tors implicated in the septic response. LPS triggers proin-
flammatory cytokine production, and also disrupts the
microcirculation by increasing vascular permeability in
experimental models [26-28]. In our study, we demonstrate
that Bev attenuates excessive vascular permeability in
Table 1 The concentration of cytokines IL-6, MCP-1 and RANTES in each group
Cytokines Control LPS LPS + Bev 1 LPS + Bev 2 Bev
IL-6 (pg/ml) 0.0 ± 0.0 2,054.3 ± 98.6 1,477.8 ± 44.6* 1,281.4 ± 25.9* 0.0 ± 0.0
MCP-1 (ng/ml) 1.42 ± 0.02 13.71 ± 0.18 10.74 ± 0.25 10.05 ± 0.13* 0.87 ± 0.02
RANTES (pg/ml) 0.0 ± 0.0 286.2 ± 4.0 240.6 ± 3.3 201.7 ± 17.2* 0.0 ± 0.0
Data are expressed as means ± SD. The levels of IL-6, MCP-1 and RANTES in HUVECs after treatment with LPS (LPS group), LPS + Bev (Bev 1 at 25 μg/ml Bev, and
Bev 2 at 50 μg/ml Bev), or Bev-only group (50 μg/ml Bev). *P <0.01 when compared to the group of LPS (n = 4).
Bev, bevacizumab; HUVECs, human umbilical vein endothelial cells; LPS, lipopolysaccharide; MCP-1, monocyte chemotactic protein-1; RANTES, regulated on
activation, normal T-cell expressed and secreted; SD, standard deviation.
Figure 3 Survival in murine sepsis models and the effects of differing doses of bevacizumab on mortality. A, Kaplan-Meier survival
analysis following cecal ligation and puncture (CLP) comparing bevacizumab (Bev)-treated animals administered 0.1 mg/kg (n = 8) or 1.0 mg/kg
(n = 8) i.p. 1 h before CLP to controls with CLP (n = 13). The group administered 0.1 mg/kg had a significantly greater survival than the CLP
controls (P <0.001). B, Kaplan-Meier survival analysis following lipopolysaccharide (LPS) injection comparing Bev-treated animals administered 0.1
mg/kg (n = 10) or 1.0 mg/kg (n = 10) i.p. 1 h before LPS treatment to mice administered LPS-only (n = 8). Administration of 0.1 mg/kg led to
significantly greater survival relative to the LPS-only group (P = 0.028).
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endotoxemia models, and is able to significantly quell the
LPS-induced inflammation in HUVECs. Soluble Flt (sFlt)-
1, a splice variant of the VEGF receptor VEGFR-1, is
secreted, binds VEGF and acts as a decoy receptor,
decreasing its net activity. In a previous study, sFlt-1 was
shown to protect mice from VEGF-induced sepsis [29] and
could play an important role in the treatment of sepsis. In
addition, Yano et al. showed that adenovirus mediated
over-expression of sFlt-1 blocked endotoxemia induced
vascular permeability and mortality in mice, and protected
against cardiac dysfunction and mortality in a CLP model
[17]. In contrast, Nolan et al. reported that blocking of
VEGF using VEGF trap (VEGFT) did not alter lung leakage
or mortality but reduced production of IL-6 and IL-10
[30]. VEGFT is a recombinant protein generated by the
fusion of two domains of VEGFR-1 and 2 attached to the
hinge region of the Fc portion of IgG1. VEGFT was ration-
ally designed as an extremely high-affinity trap for VEGF
and other VEGFR ligands. Whether the benefit of VEGFT
and Bev parallel that of sFlt-1 is not clear. Differences in
affinity for VEGF could affect survival benefit and vascular
permeability in animal models of sepsis.
How VEGF functions in sepsis is not completely under-
stood. However, significant insights regarding plasma and
pulmonary VEGF in sepsis have been garnered from ani-
mal models. Kaner et al. demonstrated that intrapulmon-
ary over-expression of VEGF results in high-permeability
edema in the lungs of mice [31], which was blocked by a
biological inhibitor of VEGF. This suggests that VEGF reg-
ulates baseline microvascular permeability and that ele-
vated alveolar VEGF levels might determine pulmonary
edema in acute respiratory distress syndrome [31]. There-
fore, ability of Bev to neutralize VEGF, -like sFlt-1, may
attenuate morbidity and mortality in severe sepsis.
Figure 4 Effects of differing bevacizumab treatment times on mortality in the murine models of sepsis. A, Delayed administration of Bev
is protective in cecal ligation and puncture (CLP). Kaplan-Meier survival analysis following CLP in mice comparing the efficacy of pre- and post-
surgical bevacizumab (Bev) treatment at various time intervals relative to the CLP control. Bev administration significantly enhanced survival
relative to the CLP controls (P = 0.006 in the pre-treated group, and P = 0.033 in the 6 h post-treated group), except for mice in which Bev
administration was delayed for 12 h (12 h delayed-treatment group, P = 0.062). B, Lethality from endotoxemia was diminished with delayed Bev
administration, but not statistically significantly so.
Figure 5 Effect of bevacizumab treatment on vascular
permeability in a mouse model of endotoxemia. Quantitation of
Evans-blue extravasation (optical density (OD) at 620 nm). Error bars
represent SD. *P <0.05 when compared to the LPS group (P = 0.011
for lung, P = 0.046 for spleen, and P <0.001 for kidney).
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In our study, survival benefits were evident in mice
given 0.1 mg/kg rather than 1.0 mg/kg Bev. Bev inhibits
the growth of human tumor cell lines in nude mice,
achieving a maximal inhibition at the dose of 1 to 2 mg/kg
twice per week [32]. Half-maximal inhibition required 0.1
to 0.5 mg/kg doses. Why the lower dose of Bev seemed
more effective than the higher dose in this study is
unclear, although there are three possible explanations:
the unique role of Bev as an inhibitor of angiogenesis
and wound healing may account for this inverted dose-
effectiveness. There are few pre-clinical reports of the
effect of the anti-VEGF antibody on wound healing. Bev
reduces the rate of spontaneous wound healing in maca-
ques [33]. Also, agents targeting VEGF have deleterious
effects on the healing of ventral hernias and colonic ana-
stomoses [34-36]. In humans, dose-limiting toxicity was
induced in locally advanced rectal cancer patients [37].
Wound-healing complications might be possible causes
for different survival benefits that are dose-dependent.
However, the finding in endotoxemia models has not been
fully explained. Reduction in intra-tumor pressure and
improved delivery of chemotherapy result in greater Bev
efficacy than induction of vascular collapse inside the
tumor [38,39]. The lower dose may have resulted in
improved delivery of antibiotics or leukocytes to clear the
infection, whereas the higher dose resulted in vascular col-
lapse, limiting delivery of antibiotics or leukocytes. Bev
was generally well tolerated in clinical studies, and a recent
study showed that the plasma VEGF level increases during
the first 48 h of human septic shock and correlates with
vascular permeability [11]. Therefore, the impact of Bev
on severe sepsis should be confirmed by further research
including determination of tissue-specific toxicities.
The current study has some limitations that need to be
addressed. First, the different sizes of groups of mice were
used in survival analyses. However, a power calculation
found that high and even statistical power could be con-
firmed. Secondly, the mechanisms of the inverted dose
response were not clearly evaluated. Furthermore, the data
presented do not support the use of Bev for the clinical
treatment of sepsis. Therefore, further studies are needed
to evaluate the optimal dosage, safety, efficacy and other
effects of Bev for sepsis.
Conclusions
This is, to our knowledge, the first report to document the
therapeutic effects of Bev in two standard murine models
of sepsis: polymicrobial sepsis resulting from a ruptured
viscus and endotoxemic sepsis. The attenuation of VEGF
activity by Bev may be an effective approach to the treat-
ment of severe sepsis in clinical settings. Further investiga-
tion of the safety and possible synergistic effects in
combination with antibiotics will be needed to determine
the feasibility of using this strategy for treatment of life-
threatening severe sepsis.
Key messages
• Bev administration significantly decreased mRNA
and protein levels of the pro-inflammatory cytokines
IL-6, MCP-1 and RANTES in HUVECs treated with
LPS when compared to LPS-only treated HUVECs.
• A dose of 0.1 mg/kg increased survival relative to
the CLP control and LPS control groups in both the
murine CLP and endotoxemia models of sepsis.
• Bev administration provides significant protection up
to 6 h after CLP, but the differences were no longer
significant compared with the LPS control group.
• Bev-treatment inhibited vascular permeability in
the lung, spleen and renal parenchyma in a mouse
model of endotoxemia.
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